Drug Profile
Interferon alpha-2b biosimilar - Virchow Group
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Virchow Group
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B; Hepatitis C
Most Recent Events
- 15 May 2015 Launched for Hepatitis B in India (Injection) before May 2015
- 15 May 2015 Launched for Hepatitis C in India (Injection) before May 2015
- 15 May 2015 Central Drugs Standard Control Organisation approves interferon alpha-2b biosimilar in India before May 2015 (Virchow Group website, May 2015)